<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mediator complex participates in transcriptional regulation by connecting regulatory DNA sequences to the <z:chebi fb="40" ids="33697">RNA</z:chebi> polymerase II initiation complex </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we discovered through exome sequencing that as many as 70% of <z:hpo ids='HP_0000131'>uterine leiomyomas</z:hpo> harbour specific mutations in exon 2 of mediator complex subunit 12 (MED12) </plain></SENT>
<SENT sid="2" pm="."><plain>In this work, we examined the role of MED12 exon 2 mutations in other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The frequency of MED12 exon 2 mutations was analysed in altogether 1158 tumours by direct sequencing </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> spectrum included <z:e sem="disease" ids="C1334699" disease_type="Neoplastic Process" abbrv="">mesenchymal tumours</z:e> (extrauterine <z:mpath ids='MPATH_425'>leiomyomas</z:mpath>, endometrial <z:mpath ids='MPATH_491'>polyps</z:mpath>, <z:hpo ids='HP_0012032'>lipomas</z:hpo>, <z:hpo ids='HP_0002891'>uterine leiomyosarcomas</z:hpo>, other <z:hpo ids='HP_0100242'>sarcomas</z:hpo>, gastro-intestinal <z:e sem="disease" ids="C0879615" disease_type="Neoplastic Process" abbrv="">stromal tumours</z:e>), <z:e sem="disease" ids="C1522458" disease_type="Neoplastic Process" abbrv="">hormone-dependent tumours</z:e> (breast and <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancers</z:e>), <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> (<z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemias</z:mpath>, <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoid <z:mpath ids='MPATH_336'>leukaemias</z:mpath>, myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo>), and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> associated with abnormal Wnt-signalling (<z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>)) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Five somatic alterations were observed: three in <z:hpo ids='HP_0002891'>uterine leiomyosarcomas</z:hpo> (3/41, 7%; Gly44Ser, Ala38_Leu39ins7, Glu35_Leu36delinsVal), and two in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (2/392, 0.5%; Gly44Cys, Ala67Val) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Somatic MED12 exon 2 mutations were observed in <z:hpo ids='HP_0002891'>uterine leiomyosarcomas</z:hpo>, suggesting that a subgroup of these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumours</z:e> may develop from a <z:mpath ids='MPATH_425'>leiomyoma</z:mpath> precursor </plain></SENT>
<SENT sid="7" pm="."><plain>Mutations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples indicate that MED12 may, albeit rarely, contribute to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
</text></document>